GT Biopharma
GTBP
40 hedge funds and large institutions have $657K invested in GT Biopharma in 2026 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 5 increasing their positions, 3 reducing their positions, and 10 closing their positions.
555% more capital inflows, than outflows
Capital inflows: $695K | Capital outflows: $106K
70% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 10
67% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 3
18% more funds holding
Funds holding: 34 → 40 (+6)
8.46% less ownership
Funds ownership: 13.58% → 5.11% (-8.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$150K |
| 2 |
Arax Advisory Partners
Denver,
Colorado
|
+$51.1K |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$25.1K |
| 4 |
I
INVST
Indianapolis,
Indiana
|
+$12.8K |
| 5 |
KP
Keel Point
Huntsville,
Alabama
|
+$11.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SRL
Scientech Research LLC
Jersey City,
New Jersey
|
-$43K |
| 2 |
Jane Street
New York
|
-$20.4K |
| 3 |
HRT Financial
New York
|
-$9K |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$8.51K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$7.95K |
GTBP Hedge Fund Activity: Q1 2026 in Review
40 of the 8,212 institutional investors tracked by Wall St. Rank reported a position in GT Biopharma (GTBP) for Q1 2026, worth a combined $657K — up 76% from $374K a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new GTBP positions and 10 closed out — a net gain of 7 holders — while 5 added to existing stakes and 3 trimmed.
The largest buyer was Geode Capital Management, adding an estimated $150K. The largest seller was Scientech Research LLC, exiting entirely with an estimated $43K sold.
- 40 institutional investors held GT Biopharma (GTBP) as of Q1 2026, up from 34 in Q4 2025.
- Funds reported $657K of GT Biopharma stock for Q1 2026, up 76% quarter-over-quarter.
- 17 funds opened new GT Biopharma positions in Q1 2026 and 10 closed out, a net change of +7 holders.
- The largest GT Biopharma buyer in Q1 2026 was Geode Capital Management, an estimated $150K added.
- The largest GT Biopharma seller in Q1 2026 was Scientech Research LLC, an estimated $43K sold.
Based on aggregated 13F filings for Q1 2026.